(Q47126394)

English

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

scientific article published on 3 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer (English)

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Andrew M. Wardley

6

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Andreas Schneeweiss

15

object named as

Andreas Schneeweiss

1 reference

Europe PubMed Central

8 January 2018

author name string

José Baselga

1

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Patricia Gómez

2

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Richard Greil

3

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Sofia Braga

4

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Miguel A Climent

5

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Bella Kaufman

7

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Salomon M Stemmer

8

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

António Pêgo

9

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Arlene Chan

10

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Jean-Charles Goeminne

11

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Marie-Pascale Graas

12

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

M John Kennedy

13

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Eva Maria Ciruelos Gil

14

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Angela Zubel

16

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Jutta Groos

17

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Helena Melezínková

18

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Ahmad Awada

19

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

language of work or name

0 references

publication date

3 June 2013

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

Journal of Clinical Oncology

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

31

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

20

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

2586-2592

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Directed therapy of subtypes of triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Triple-negative breast cancer: role of specific chemotherapy agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

EGFR associated expression profiles vary with breast tumor subtype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

23 May 2018

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

15 August 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

15 August 2018

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

15 August 2018

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

15 August 2018

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705191

1 December 2018

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.46.2408

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

1 reference

Europe PubMed Central

8 January 2018

http://europepmc.org/abstract/PMC/5705191

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47126394&oldid=2142307007"